

University of Groningen

Determinants of Adherence to Treatment in Hypertensive Patients of African Descent and the Role of Culturally Appropriate Education

Meinema, Jennita G.; van Dijk, Nynke; Beune, Erik J. A. J.; Jaarsma, Alexandra; van Weert, Henk C. P. M.; Haafkens, Joke A.

Published in:
Plos one

DOI:
[10.1371/journal.pone.0133560](https://doi.org/10.1371/journal.pone.0133560)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Meinema, J. G., van Dijk, N., Beune, E. J. A. J., Jaarsma, D. A. D. C., van Weert, H. C. P. M., & Haafkens, J. A. (2015). Determinants of Adherence to Treatment in Hypertensive Patients of African Descent and the Role of Culturally Appropriate Education. *Plos one*, 10(8), [0133560]. DOI: 10.1371/journal.pone.0133560

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Determinants of Adherence to Treatment in Hypertensive Patients of African Descent and the Role of Culturally Appropriate Education

Jennita G. Meinema^{1*}, Nynke van Dijk¹, Erik J. A. J. Beune², Debbie A. D. C. Jaarsma³, Henk C. P. M. van Weert¹, Joke A. Haafkens¹

1 Department of General Practice/Family Medicine, Academic Medical Center-University of Amsterdam, Amsterdam, the Netherlands, **2** Department of Social Medicine, Academic Medical Center-University of Amsterdam, Amsterdam, the Netherlands, **3** Department of Evidence-based medical education, University Medical Center of Groningen, Groningen, the Netherlands

* j.g.meinema@amc.uva.nl



Abstract

Background

In Western countries, better knowledge about patient-related determinants of treatment adherence (medication and lifestyle) is needed to improve treatment adherence and outcomes among hypertensive ethnic minority patients of African descent.

Objective

To identify patient-related determinants of adherence to lifestyle and medication recommendations among hypertensive African Surinamese and Ghanaian patients with suboptimal treatment results (SBP \geq 140) living in the Netherlands and how culturally appropriate hypertension education (CAHE) influenced those determinants.

Methods

This study analysed data of 139 patients who participated in the CAHE trial. Univariate logistic regression analysis was used to measure the association between patient-related determinants (medication self-efficacy, beliefs about medication and hypertension, social support, and satisfaction with care) and treatment adherence. We also tested whether CAHE influenced the determinants.

Results

Medication self-efficacy and social support were associated with medication adherence at baseline. At six months, more medication self-efficacy and fewer concerns about medication use were associated with improved medication adherence. Self-efficacy was also associated with adherence to lifestyle recommendations at baseline. CAHE influenced patients' illness perceptions by creating more understanding of hypertension, its chronic character, and more concerns about the associated risks.

OPEN ACCESS

Citation: Meinema JG, van Dijk N, Beune EJAJ, Jaarsma DADC, van Weert HCPM, Haafkens JA (2015) Determinants of Adherence to Treatment in Hypertensive Patients of African Descent and the Role of Culturally Appropriate Education. PLoS ONE 10(8): e0133560. doi:10.1371/journal.pone.0133560

Editor: Hajo Zeeb, Leibniz Institute for Prevention Research and Epidemiology (BIPS), GERMANY

Received: March 5, 2015

Accepted: June 28, 2015

Published: August 12, 2015

Copyright: © 2015 Meinema et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Some data are within the paper and its Supporting Information files. The underlying raw data are available upon request from the corresponding author, due to patient confidentiality concerns.

Funding: This study was funded by ZonMw, the Netherlands organisation for health research and development (grants no. 122000008 and 12010095425), <http://www.zonmw.nl/en/>. The study sponsor carried out annual reviews of the study's progress but had no active role in the study design,

data collection, analysis and reporting, nor in the preparation of this manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Conclusion

In this high-risk population, health care providers can support medication adherence by paying attention to patients' medication self-efficacy, the concerns they may have about medication use and patients' perceptions on hypertension. The CAHE intervention improved patients' perception on hypertension.

Introduction

Hypertension is a major risk factor for cardiovascular disease and especially stroke. [1] To reduce the risk of cardiovascular disease, hypertensive patients must be treated appropriately, either through lifestyle interventions alone or in combination with medication. [2] Treatment of hypertension fails when patient-related barriers towards treatment are not recognised. A better assessment and understanding of these barriers will allow optimal tailoring of interventions. [3]

In Western countries, hypertension is more common among ethnic minority groups of African descent than among whites. [4–6] Agyemang et al. reported that the prevalence of hypertension among native Dutch adults was lower than among adults of African-Surinamese and Ghanaian descent and that these ethnic minority groups had higher levels of hypertension awareness. [7] Among treated hypertensive patients, blood pressure control rates were significantly lower for the African Surinamese and the Ghanaians. [7–9] This demonstrates a need to address barriers to blood pressure control among African Surinamese and Ghanaian patients treated for hypertension. Poor adherence to treatment recommendations (medication and lifestyle) has been identified as a major modifiable cause of differences in blood pressure control rates in general [10, 11] and for those who belong to ethnic minority groups in particular [12, 13]. Knowledge of the relation between patient-related barriers and adherence could be used to enhance treatment-adherence among patients with hypertension. [11]

Since studies in several countries have shown that adherence to hypertension treatment recommendations is generally lower among disadvantaged populations, such as ethnic minority groups, it has been hypothesised that patients who belong to these groups may benefit from culturally tailored educational approaches. [14–17] Additionally, cultural factors have been shown to influence patients' beliefs and practices concerning hypertension. [18–21] We have previously developed a protocol for culturally adapted hypertension education (CAHE) to support adherence to lifestyle and medication recommendations and blood pressure control in hypertensive patients of African descent. [22] The protocol combines the principles of motivational interviewing (5 A's; i.e. Ask, Assess, Advise, Assist, and Arrange) [23] with those from Arthur Kleinmans' model. Kleinmans' model proposes that patient perceptions of disease and treatment can differ substantially from those of their healthcare providers. [24] The protocol focuses on asking essential questions to generate understanding by the patients about their health beliefs and their own condition in a multi-cultural environment. The main goal of the CAHE intervention was to improve patients' health behaviour and, in turn, their blood pressure. Using a cluster randomised controlled trial we showed that CAHE leads to a higher reduction in diastolic blood pressure (DBP) (5.73 mmHg vs. 1.70 mmHg) and better adherence to lifestyle recommendations among African-Surinamese and Ghanaian patients with uncontrolled hypertension when compared to standard care. [22, 25]

Research based on models of health behaviour has provided evidence that adherence to treatment is a self-regulatory process and that patients' ideas about their illness (*the*

consequence, timeline, personal-control, treatment-control and identity) and medications are predictive of adherence to medication and lifestyle recommendations. [18–21, 26] In addition, several studies have shown that self-efficacy influences patients' ability and skills to continue treatment. [27–29] Also satisfaction with care and social support have been identified as factors influencing adherence. [9, 18, 30–32] However, the pathway from patient education to adherence (and hypertension control) is complex and still poorly understood. This study aims at deepening our understanding of this pathway, in particular for the treatment of hypertension in a migrant population at high risk of cardiovascular disease. We report for the first time focus areas for the treatment of this population. To this end we performed a secondary analysis of the CAHE trial with the aim to identify 1) the (best) subset of determinants that predicted adherence to medication and lifestyle recommendations prior to the intervention, 2) how changes in those determinants were associated with adherence to medication and lifestyle recommendations after the intervention (at six months), and 3) we evaluated the role of CAHE by investigating to what extent this intervention had influenced any of the determinants of adherence, and particularly those that were associated with an improvement in treatment adherence.

Methods

Study design

This study analyses data that were collected among participants who completed the CAHE study. Full details of the design and methods of this cluster-randomised trial and the content of CAHE intervention have been published previously. [22, 25] Briefly, the study tested the effect of the CAHE intervention on blood pressure control and treatment adherence among Surinamese and Ghanaian patients with uncontrolled hypertension from four Dutch primary health care centres (PHCC) in Southeast Amsterdam. PHCCs allocated to the control group provided standard (guideline based) hypertension care to the study participants and PHCCs allocated to the intervention group provided usual care and three nurse-led individual CAHE sessions to study participants. [33] At the start of the intervention (t0) and after 6 months (t1), BP and other physiological measures were assessed and information on self-reported adherence to lifestyle and medication and patient-related determinants of adherence (perception on medication and hypertension, self-efficacy, social support, satisfaction with care) was collected through validated questionnaires. (*Table A in S1 File*) Socio-demographic data were obtained at the start of the intervention. The research assistants who performed the baseline and follow-up assessments received a specific training for the purpose of this study and were blinded to the study conditions. [25] All data was entered into SPSS Data Entry 4.0 (Ref: SPSS Inc, Chicago IL, USA).

For this paper we performed a stepwise analysis of 1) the association between background characteristics and patient-related determinants of adherence and self-reported adherence to medication and lifestyle recommendations at baseline, 2) the association between changes in patient-related determinants of adherence and changes in self-reported adherence of medication and lifestyle recommendations at six months and 3) the influence of the CAHE intervention on changes in patient-related determinants of adherence. (*Fig 1*)

Variables and outcome measurements

Adherence to lifestyle and medication recommendations. *Self-reported adherence to medication recommendations* was assessed with the eight-item Morisky medication adherence scale (MMAS-8). [34] This scale has been well validated in several studies among African-American populations. [9, 35–37] The MMAS-8 asks patients to respond with “yes” or “no” to a set of 7 questions and to one 5-point Likert scale question. The score for full adherence is 8,




Fig 1. A schematic overview of the scope of this study. Fig 1 legend: A Schematic overview of the scope of this study and the study of Beune et al. [22] Beune et al. showed positive correlations (solid arrows) of the CAHE intervention with adherence to lifestyle recommendations. Additionally, CAHE was shown to lower diastolic blood pressure (blunt arrows). The dashed arrows indicate the research questions of this study. Research question 1 and 2 analyse which determinants are associated with adherence to medication and lifestyle recommendations. Research question 3 answers which determinants the CAHE intervention influences in order to increase adherence to medication and lifestyle recommendations.

doi:10.1371/journal.pone.0133560.g001

with lower scores indicating a poorer level of adherence with a lower boundary of zero. In this study patients were described as non-adherent if they had an MMAS-8 score < 6 and as adherent if their score was ≥ 6. When patients had become more adherent between T0 and T1 or remained on the maximum score, they were categorised as ‘improved adherence’.

Self-reported adherence to lifestyle recommendations was assessed with a three-item scale derived from the Morisky scale. [38] This scale contains three questions: 1) Have you been advised by your PN/GP about smoking, nutrition, alcohol, weight control and/or physical activity (Yes/No)? 2) If yes, what advice was given? 3) To what extent did you follow this advice (range: never (1)–always (4))? On the basis of answers to these questions a composite score for adherence to lifestyle recommendations was computed (range: 1–4). Patients with scores 1 and 2 were categorised as non-adherent and those with scores 3 and 4 were categorised as adherent to lifestyle recommendations. When patients had become more adherent between T0 and T1 or remained on the maximum score, they were categorised as ‘improved adherence’. (Results of a psychometric analysis of these outcome measures are shown in Tables D and E in [S1 File](#)).

Background characteristics and patient-related determinants of adherence. Self-reported data on age, gender, educational level, financial status, duration of hypertension, and years living in the Netherlands were collected at the start of the study, to describe background characteristics of the study sample. (Table B in [S1 File](#))

The following five measures were used to obtain information on potential patient-related determinants of adherence (Table A in [S1 File](#)):

Perceptions of hypertension were assessed with the Brief Illness Perceptions Questionnaire (IPQ-brief). The validity and the reliability of this questionnaire is well established The IPQ-brief asks patients to provide information about 8 dimensions of illness (hypertension) that can be answered on a 5-point Likert scale. Five dimensions are related to cognitive illness representations (the perceived consequence, timeline, personal-control, treatment-control and identity), two dimensions are related to emotional representations (respondents’ emotions and concerns about the illness) and one dimension is related to illness comprehensibility (coherence). [39] Separate scores for the 8 dimensions of illness perception and an overall score were computed. The scores represent the degree to which the illness is perceived as threatening (high scores) or benign (lower scores).

Medication self-efficacy was assessed with the Medication Adherence Self-Efficacy Scale (MASES-R). This scale shows good internal consistency, predictive validity, and convergent validity in African-American patients with hypertension. [40] The patients' confidence in their ability to take medicine on time in various situations is measured with 13 questions, that can be answered on a 4-point Likert scale. [40] Scores were totalled and the mean score reflects the amount of medication self-efficacy, with higher scores designating higher self-efficacy.

Beliefs about medication were assessed with the ten-item Beliefs about Medicines Questionnaire (BMQ). [26] This instrument has good internal consistency and validity. [41, 42] The first scale (Specific-necessity) of this questionnaire assesses hypertensive patients' beliefs about how necessary it is to take medications in order to improve/maintain their health. The second scale (Specific-concern) assesses respondents' "concerns" about potential adverse consequences from taking their medications. The BMQ uses 5-point Likert questions ranging from 1 = "strongly disagree" to 5 = "strongly agree". The respondents' scores on each item were totalled. Higher scores indicate stronger beliefs about the necessity of taking medicines and concerns about adverse effects of medications.

The amount of *Social Support* patients experienced when dealing with their condition was assessed using the validated 12-item Duke Social Support Scale (DUSOCS). [43] As demonstrated by previous studies in hypertensive African-American patients, this scale has good validity and reliability [35] DUSOCS is divided into two subscales: social support from family (6-item scale) and social support from others than family (5-item scale). A higher total score reflects more social support. The open question that is used in DUSOCS was not taken into account in our analysis.

Satisfaction with care was measured using five items of the Consumer Quality Index-Diabetes [44] and five items of the Quote Migrant. [45] Similar Consumer Quality Index instruments have demonstrated good construct and discriminating validity and internal consistency in previous studies [46, 47] The Quote Migrant has been developed to measure the quality of care experienced by migrants groups in the Netherlands. [45] A higher score reflects a higher satisfaction with care.

Statistical analysis

Data were analysed using SPSS version 19 (Ref: SPSS Inc, Chicago IL, USA). The distributions of continuous data were graphically assessed. Means and standard deviations were reported for normally distributed data and medians and quartiles for non-normal distributed data.

Univariate logistic regression analysis was conducted to assess the association between each determinant of adherence and each outcome variable (adherence to medication or lifestyle recommendations). Since the number of participants in the study was low, relative to the number of measured determinants, [25] a p-value of 0.3 in the univariate analysis was used as an upper threshold for inclusion in the multivariate logistic regression model. Using a stepwise backward (LR) method, variables were selected for the final model. Only determinants that were statistically significant ($p < 0.05$) contributors to the multivariate model were considered to be related to adherence. The same procedure was used to examine the association between changes in determinants of adherence and changes in adherence to medication and lifestyle recommendations.

To assess the influence of the CAHE intervention on the determinants of adherence we compared the change in the determinants between the intervention and the control group. Scores were compared using a chi-square test for categorical data and an independent t-test for normally distributed continuous data.

The study protocols were approved by the medical ethics committee of the Academic Medical Center in Amsterdam (protocol ID MEC 09/070 # 09.17.0725) and CCMO

(NL27507.018.09). This trial is registered at the ISRCTN Register under registration number ISRCTN35675524 (<http://www.controlled-trials.com/ISRCTN35675524>). In accordance with the Declaration of Helsinki, written informed consent was obtained from all patients.

Results

Description of the population

Patients' background characteristics at baseline are shown in Table B in [S1 File](#). The average age of the patients was 53.9±9.8 years, and 47.5% were male. [Table 1](#) shows that at the start of the intervention 58.0% and 64.7% of the patients were categorised as adherent to medication and lifestyle recommendations, respectively. Patients who were adherent to medication recommendations reported a longer duration of stay in the Netherlands (mean difference: 4.5 years (95% CI: 0.68–8.3) and less financial difficulties (mean difference: 0.17 (95% CI: 0.01–0.33) compared to non-adherent patients. All other baseline differences between the adherent and non-adherent group are marginal and summarised in Table B in [S1 File](#). After six months diastolic, but not systolic blood pressure was positively correlated with adherence to medication and lifestyle recommendations. ([Table C in S1 File](#))

Treatment adherence and determinants of adherence

Association between treatment adherence at the start of the intervention and background characteristics and patient-related determinants of adherence. At baseline patients

Table 1. Patient scores on measures for treatment adherence and patient-related determinants of adherence taken at baseline and six months (N = 139).

Measures		Start of intervention	After six months	Range	
Adherence	<i>Adherent to medication, n (%)</i>	65 (58.0%)	79 (65.3%)		
	<i>Adherent to lifestyle advice, n (%)</i>	75 (64.7%)	87 (75.5%)		
Positive change in medication adherence, n (%):			63 (57.3%)		
Positive change in lifestyle adherence, n (%):			55 (56.7%)		
Social support family, mean (±SD)		39.5 (±28.3)	41.3 (±25.9)	0–100	
Social support others, mean (±SD)		25.9 (±23.2)	29.3 (±23.8)	0–100	
Illness perception		<i>Illness perception overall score (IPQ-Brief), mean (±SD)</i>			
		36.6 (±11.2)	34.3 (±10.2)	0–80	
Per item:					
		<i>Consequences</i>	5.0 (±3.1)	5.2 (±2.8)	0–10
		<i>Timeline</i>	6.0 (±3.2)	6.6 (±3.0)	0–10
		<i>Personal-control</i>	6.3 (±2.8)	7.4 (±2.1)	0–10
		<i>Treatment-control</i>	7.4 (±2.3)	8.1 (±1.7)	0–10
		<i>Identity</i>	4.1 (±3.1)	4.1 (±2.7)	0–10
		<i>Illness coherence</i>	7.2 (±2.9)	7.5 (±2.7)	0–10
		<i>Emotions</i>	5.0 (±3.4)	4.7 (±3.2)	0–10
		<i>Illness concerns</i>	7.2 (±3.0)	6.9 (±2.9)	0–10
Medication self-efficacy, mean (±SD)		3.4 (±0.7)	3.5 (±0.6)	0–4	
Satisfaction with care		<i>Satisfaction with healthcare—CQI</i>			
		18.4 (±2.4)	18.3 (±2.6)	6–20	
		<i>Satisfaction with healthcare—Quote migrant</i>			
		12.2 (±5.9)	13.1 (±5.7)	0–20	
Beliefs about medication		<i>Concerns about medication use—BMQ Concerns</i>			
		13.8 (±4.3)	13.6 (±4.4)	5–25	
		<i>Necessity of medication use—BMQ Necessity</i>			
		16.4 (±5.0)	16.3 (±4.7)	5–25	

SD = Standard deviation

doi:10.1371/journal.pone.0133560.t001

Table 2. Association between adherence to medication and lifestyle recommendations and determinants at start of intervention.

Determinants of medication adherence * ¹	Exp. B (95% Confidence Interval)	P-value
Medication self-efficacy	7.62 (3.00–19.35)	<0.001
Social support—others	0.98 (0.96–1.00)	0.046
Determinants of lifestyle adherence * ²	Exp. B (95% Confidence Interval)	P-value
Medication self-efficacy	2.16 (1.10–4.27)	0.03
Social support—others	1.02 (1.00–1.04)	0.10

*¹ Multiple logistic regression analysis, backward LR. Model included variables: Medication self-efficacy, Illness perception overall score (IPQ-brief), Social support—family, Social support—others, Satisfaction-healthcare. And not modifiable factors: age, financial status, duration of hypertension, and years in Netherland.

*² Multiple logistic regression analysis, backward LR. Model included variables: Medication self-efficacy, Social support—others, Social support—family, satisfaction healthcare. And non-modifiable factors: Age and educational level.

doi:10.1371/journal.pone.0133560.t002

who were adherent to medication- and lifestyle recommendations reported higher medication self-efficacy as compared to non-adherent patients ($p < 0.001$ and $p = 0.026$, resp.). Patients who were adherent to medications experienced less social support from non-family members as compared to non-adherent patients ($p = 0.046$). (Table 2) Adherence was not significantly associated with the other potential patient-related determinants.

Association between changes in patient-related determinants of adherence and changes in treatment adherence at six months. Table 3 shows that patients who showed an higher level of medication self-efficacy after six months were more likely to report an improvement in adherence to medication than those who did not ($p = 0.031$). Additionally, older patients were more likely to show an improvement in medication adherence than younger patients ($p = 0.033$). Patients who were more concerned about their medication use at baseline (BMQ-concern) were less likely to report an improvement in medication adherence. In this group the reported level of medication adherence remained low or decreased ($p = 0.04$). There were no significant associations between changes in determinants of adherence and changes in adherence to lifestyle recommendations.

Table 3. Associations between changes in adherence to medication and lifestyle recommendations and changes in determinants of adherence at six months.

Determinants of medication adherence * ¹	Exp. B (95% Confidence Interval)	P-value
Change in medication self-efficacy	2.64 (1.09–6.39)	0.03
Change in concerns about medication use	0.89 (0.79–0.99)	0.04
Change in illness perceptions	1.04 (0.99–1.09)	0.10
Age	1.05 (1.00–1.11)	0.03
Determinants of lifestyle adherence * ²	Exp. B (95% Confidence Interval)	P-value
Change in medication self-efficacy	1.56 (0.69–3.53)	0.24

*¹ Multiple logistic regression analysis, backward LR. Model included variables: the change in medication self-efficacy, Illness perception overall score (IPQ-brief)-, and beliefs about medication- (BMQ-concern). And non-modifiable factors: age, educational level and duration of hypertension.

*² Multiple logistic regression analysis, backward LR. Model included variables: the change in medication self-efficacy. And non-modifiable factors: Age and educational level.

doi:10.1371/journal.pone.0133560.t003

Table 4. The mean changes in patient-related determinants of adherence for patients allocated to CAHE (intervention) or usual care (control).

Variable	Mean (SD)		P value	Mean difference (95% CI)
	Intervention	Control		
Change in social Support	2.78 (18.66)	2.99 (22.25)	0.95	-0.20 (-7.22–6.81)
Change in concerns about medication use	-0.45 (3.94)	-0.33 (4.23)	0.88	-0.11 (-1.68–1.45)
Change in necessity of medication use	0.38 (4.68)	-0.43 (3.73)	0.31	0.81 (-0.77–2.40)
Change in satisfaction healthcare	0.12 (2.43)	-0.39 (2.61)	0.25	0.51 (-0.35–1.36)
Change in satisfaction migrant	1.20 (3.48)	0.55 (4.11)	0.33	0.64 (-0.66–1.95)
Change in self-efficacy	0.085 (0.68)	0.088 (0.44)	0.98	-0.002 (-0.22–0.22)
Change in illness perceptions overall	-1.88 (9.13)	-3.18 (9.43)	0.42	1.30 (-1.87–4.47)
Change in consequence	0.41 (2.80)	-0.15 (2.85)	0.31	0.55 (-0.40–1.51)
Change in timeline	0.94 (2.51)	0.15 (2.85)	0.05	0.79 (0.00–1.59)*
Change in personal-control	1.34 (3.07)	0.82 (2.77)	0.25	0.51 (-0.48–1.51)
Change in treatment-control	0.97 (2.32)	0.54 (2.54)	0.31	0.43(-0.40–1.25)
Change in identity	0.33 (2.93)	-0.44 (3.29)	0.15	0.77 (-0.28–1.83)
Change in coherence	0.94 (3.12)	-0.22 (3.02)	0.03	1.16 (0.12–2.20)*
Change in emotions	-0.06 (3.36)	-0.72 (3.10)	0.23	0.66 (-0.43–1.76)
Change in illness concern	0.14 (2.74)	-0.87 (2.77)	0.03	1.01 (0.08–1.94)*

Comparison of the CAHE and usual care groups of their change in determinants at the start of the intervention and after 6 months

doi:10.1371/journal.pone.0133560.t004

Influence of the CAHE intervention on patient-related determinants of adherence.

Table 4 shows that patients who had received CAHE reported a better understanding of hypertension (IPQ-coherence (p = 0.028)), and more concerns about their hypertension than those in the control group (IPQ-illness concern (p = 0.033) and they better realized that hypertension is a chronic disease (p = 0.05)). However, there were no other statistically significant differences in scores on patient-related determinants of adherence between the two groups.

Discussion and Conclusion

This study examined the pathway from patient education (CAHE) to adherence via patient-related determinants of adherence, among treated hypertensive patients of African descent from Dutch general practices with suboptimal treatment control (Fig 1). We found that medication self-efficacy and social support were the main determinants of adherence to lifestyle and medication recommendations at baseline. An increase in self-efficacy and a decrease in concern about medication use during the course of the clinical trial, led to an improvement in medication adherence. We found that the CAHE intervention did not significantly influence the aforementioned determinants of adherence. However, CAHE did improve patients’ illness perceptions, in terms of a better understanding of hypertension, more concerns about the associated risks and more awareness of the chronic character of hypertension.

Comparison with other studies

This study demonstrates that patient’s medication self-efficacy positively influences adherence to antihypertensive medication. Similar results have been reported by studies on adherence [27, 48]: The more confident patients are that they will be able to take their medications in different situations, the more likely they are to be adherent. This is also consistent with findings from studies on other chronic diseases, such as rheumatoid arthritis, asthma, depression, [28, 32, 49, 50] and with studies on hypertension in African American patients. [27, 51, 52]

Our study suggests that adherent patients experienced a lower level of social support from people outside their families. Interestingly, this contrasts findings by Maguire et al., [53] who showed that adherent patients experience greater levels of social support. Although this last finding seems plausible, previous studies have shown that, especially in ethnic minority populations that were the focus of this study, talking about one's health problems to people outside the immediate family might be a taboo. Patients may fear that outsiders will view the fact that they have hypertension as an indication that their family suffers from financial problems or stress. [19, 54] This might explain the contrasting findings of Maguire et al. [53] and the present study.

In line with our finding that a lower level of concerns about medications is associated with improved adherence, a recent meta-analysis of 94 studies, that used the BMQ, also demonstrated that people with fewer concerns about their treatment show higher adherence to treatment. [55] This means it is important for health care providers to discuss cultural specific concerns about antihypertensives with patients from ethnic minority populations. Concerns about the side effects of medication, such as loss of sexual performance, or preference for traditional remedies, [18] may offer one possible explanation for the low rates of hypertension control found among African-Surinamese and Ghanaian men recently in the Netherlands. [56]

The study of Serour et al. [57] concluded that stress was mostly reported as the determinant for adherence to lifestyle recommendations. However, information on stress was not present in our data set. Since none of our examined determinants of adherence we examined in this study significantly explains the variation in adherence to lifestyle recommendations, stress (as reported by Serour et al. [57]) remains the only known determinant for lifestyle adherence.

Study weaknesses and strengths

To our knowledge this is the first study that examines patient-related determinants of hypertension treatment adherence among ethnic minority patients of African descent with uncontrolled blood pressure outside the US. In the CAHE study self-report instruments for assessing adherence to medications and lifestyle recommendations have been used. The self-reported format to acquire data has general advantages and disadvantages. [58] To obtain a high level of reliability all determinants were tested using multiple questions with validated questionnaires (*Table A in S1 File*). Questions regarding lifestyle adherence were an exception since this scale was not validated. [25] However, the normal distributed outcomes 'lifestyle adherence' and 'change in lifestyle adherence' both provide Cronbach's alpha that ensure enough confidence to use this instrument. (*Tables D and E in S1 File*)

The used Morisky scale for assessing lifestyle adherence is of a complex nature since it summarizes multiple items of lifestyle adherence (smoking, nutrition, alcohol, weight control and/or physical activity). Preferably the association of each item with the possible determinants would be tested individually on each item, which is unfeasible due to the limited population size.

Since this study is a secondary analysis, some measurements and instruments are not the best imaginable fit to obtain the answers to our research questions. Considering 'medication adherence' the actual medication intake would be a preferred measure, and also for 'lifestyle adherence' a more objective measurement would be preferred.

The self-efficacy reported for both lifestyle and medication adherence is measured with the MASES-R. Since MASES-R is tailored to measure medication adherence, we can't state that CAHE is not associated with lifestyle adherence self-efficacy. A possible explanation that CAHE did not affect medication-self efficacy is the limited room for improvement, as the level of medication self-efficacy was already very high at the start of the intervention (3.4 out of 4-point Likert scales).

The BMQ used to measure beliefs about medication was shown to be insufficient to capture cultural variations in medication beliefs. [55] As CAHE particularly targets culturally specific perceptions of medications the BMQ might be unsuitable to evaluate CAHE.

We have chosen the MMAS-8 for measuring medication adherence because the instrument has been well validated and had reported good predictive power. [9, 35–37] However it should be noted that some studies warn for overestimation of adherence by MMAS-8. [59]

Due to the relatively low numbers of participants we were forced to reduce the number of determinants that could be taken into consideration within our analysis. By excluding some of the determinants based on univariate relations, we also excluded interaction terms involving these determinants.

Practice implications

The development of more effective methods for addressing treatment adherence among hypertensive patients of African descent is a priority for research and practice in Western countries. [7, 60] Our study suggest that interventions to support optimal adherence to prescribed medications are likely to be more successful in this population if health care professionals discuss patients' concerns about medications and confidence in the ability to take medication (self-efficacy). While a previous study already has shown that CAHE can lead to greater adherence to lifestyle changes, [11, 18, 19] the present study suggests that this educational approach also leads to a better understanding of hypertension, and increase in concerns about the associated risks of hypertension and more awareness that hypertension can be controlled but not cured. Education should be targeted at the understanding that hypertension is not a disease in itself, but treatment is necessary to prevent events in the future, events that can be avoided. This is important since patients often stop taking medication or stop implementing lifestyle changes when their blood pressure is regulated as they believe hypertension is cured. These misconceptions about the nature and course of hypertension can negatively affect treatment adherence. [11, 18, 19] A possible option to tackle misconceptions and concerns about hypertension are shared medical appointments, which are shown to have a positive impact. [61, 62] As concerns about medication (and especially side-effects) lead to poor adherence and patients often do not mention (fear of) side-effects by themselves, doctors should discuss side-effects on a regular basis.

Conclusion

Our study deepens the understanding of the pathway from patient education (CAHE) to adherence to lifestyle and medication recommendations for hypertension in ethnic minority patients of African descent with uncontrolled blood pressure. Firstly, more medication self-efficacy and less social support from people outside the family are associated with higher adherence to medication and lifestyle recommendations. Secondly, improvement in medication self-efficacy and decrease in concerns about medication is associated with increased medication adherence. Thirdly, the CAHE intervention appears to have a beneficial effect on patients' illness perceptions, by contributing to a better understanding of hypertension and concerns about the associated risks, but not on patients' medication self-efficacy or their concerns about medication.

Supporting Information

S1 File. Table A: Instruments for measuring patient-related determinants. Table B: Patient Characteristics at the start of the intervention (N = 139). Table C: Association between blood pressure and adherence. Table D: Extra information about outcome measure

‘Lifestyle adherence’. Table E: Extra information about outcome measure ‘Change in Lifestyle adherence’.

(DOC)

S1 Text. Dutch abstract.

(DOC)

Acknowledgments

We acknowledge Jacob Mohr for his help by the statistical analysis.

Author Contributions

Conceived and designed the experiments: JH EB. Performed the experiments: JH EB JM NvD. Analyzed the data: JM NvD. Contributed reagents/materials/analysis tools: HvW DJ. Wrote the paper: JH EB HvW JM DJ NvD.

References

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of hypertension*. 2013; 31(7):1281–357. doi: [10.1097/01.hjh.0000431740.32696.cc](https://doi.org/10.1097/01.hjh.0000431740.32696.cc) PMID: [23817082](https://pubmed.ncbi.nlm.nih.gov/23817082/).
2. World Health O. *Prevention of Cardiovascular Disease. Pocket Guidelines for assessment and management of cardiovascular risk*. WHO press. 2007.
3. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? *European heart journal*. 2013; 34(17):1262–9. doi: [10.1093/eurheartj/ehs481](https://doi.org/10.1093/eurheartj/ehs481) PMID: [23376448](https://pubmed.ncbi.nlm.nih.gov/23376448/).
4. Agyemang C, Bhopal R. Is the blood pressure of people from African origin adults in the UK higher or lower than that in European origin white people? A review of cross-sectional data. *JHumHypertens*. 2003; 17(8):523–34. doi: [10.1038/sj.jhh.1001586](https://doi.org/10.1038/sj.jhh.1001586) 1001586 [pii].
5. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. *JAMA*. 2010; 303(20):2043–50. doi: [10.1001/jama.2010.650](https://doi.org/10.1001/jama.2010.650) PMID: [20501926](https://pubmed.ncbi.nlm.nih.gov/20501926/).
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003; 289(19):2560–72. doi: [10.1001/jama.289.19.2560](https://doi.org/10.1001/jama.289.19.2560) PMID: [12748199](https://pubmed.ncbi.nlm.nih.gov/12748199/).
7. Agyemang C, Kieft S, Snijder MB, Beune EJ, van den Born BJ, Brewster LM, et al. Hypertension control in a large multi-ethnic cohort in Amsterdam, The Netherlands: The HELIUS study. *Int J Cardiol*. 2015; 183C:180–9. doi: [10.1016/j.ijcard.2015.01.061](https://doi.org/10.1016/j.ijcard.2015.01.061) PMID: [25679990](https://pubmed.ncbi.nlm.nih.gov/25679990/).
8. Agyemang C, Attah-Adjepong G, Owusu-Dabo E, De-Graft Aikins A, Addo J, Edusei AK, et al. Stroke in Ashanti region of Ghana. *Ghana medical journal*. 2012; 46(2 Suppl):12–7. PMID: [23661812](https://pubmed.ncbi.nlm.nih.gov/23661812/); PubMed Central PMCID: PMC3645146.
9. Schoenthaler A, Chaplin WF, Allegrante JP, Fernandez S, Diaz-Gloster M, Tobin JN, et al. Provider communication effects medication adherence in hypertensive African Americans. *PatientEducCouns*. 2009; 75(2):185–91. S0738-3991(08)00527-2 [pii];doi: [10.1016/j.pec.2008.09.018](https://doi.org/10.1016/j.pec.2008.09.018)
10. De GS, Sabate E. Adherence to long-term therapies: evidence for action. *EurJCardiovascNurs*. 2003; 2(4):323. S1474515103000914 [pii].
11. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. *PLoS One*. 2014; 9(1):e84238. doi: [10.1371/journal.pone.0084238](https://doi.org/10.1371/journal.pone.0084238) PMID: [24454721](https://pubmed.ncbi.nlm.nih.gov/24454721/); PubMed Central PMCID: PMC3893097.
12. Lewis LM, Ogedegbe C, Ogedegbe G. Enhancing adherence of antihypertensive regimens in hypertensive African-Americans: current and future prospects. *ExpertRevCardiovascTher*. 2012; 10(11):1375–80. doi: [10.1586/erc.12.138](https://doi.org/10.1586/erc.12.138)

13. Odedosu T, Schoenthaler A, Vieira DL, Agyemang C, Ogedegbe G. Overcoming barriers to hypertension control in African Americans. *CleveClinJMed*. 2012; 79(1):46–56. 79/1/46 [pii];doi: [10.3949/ccjm.79a.11068](https://doi.org/10.3949/ccjm.79a.11068)
14. Cooper LA, Hill MN, Powe NR. Designing and evaluating interventions to eliminate racial and ethnic disparities in health care. *JGenInternMed*. 2002; 17(6):477–86. jgi10633 [pii].
15. Netto G, Bhopal R, Lederle N, Khatoon J, Jackson A. How can health promotion interventions be adapted for minority ethnic communities? Five principles for guiding the development of behavioural interventions. *Health PromotInt*. 2010; 25(2):248–57. daq012 [pii];doi: [10.1093/heapro/daq012](https://doi.org/10.1093/heapro/daq012)
16. Connell P, Wolfe C, McKeivitt C. Preventing stroke: a narrative review of community interventions for improving hypertension control in black adults. *Health SocCare Community*. 2008; 16(2):165–87. HSC737 [pii];doi: [10.1111/j.1365-2524.2007.00737.x](https://doi.org/10.1111/j.1365-2524.2007.00737.x)
17. Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. *Journal of clinical hypertension*. 2006; 8(3):174–80. PMID: [16522994](https://pubmed.ncbi.nlm.nih.gov/16522994/).
18. Beune EJ, Haafkens JA, Agyemang C, Schuster JS, Willems DL. How Ghanaian, African-Surinamese and Dutch patients perceive and manage antihypertensive drug treatment: a qualitative study. *JHypertens*. 2008; 26(4):648–56. doi: [10.1097/HJH.0b013e3282f4d20b](https://doi.org/10.1097/HJH.0b013e3282f4d20b) 00004872-200804000-00008 [pii].
19. Beune EJ, Haafkens JA, Schuster JS, Bindels PJ. 'Under pressure': How Ghanaian, African-Surinamese and Dutch patients explain hypertension. *JHumHypertens*. 2006; 20(12):946–55. 1002094 [pii];doi: [10.1038/sj.jhh.1002094](https://doi.org/10.1038/sj.jhh.1002094)
20. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrante JP. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. *EthnDis*. 2004; 14(1):3–12.
21. Kressin NR, Orner MB, Manze M, Glickman ME, Berlowitz D. Understanding contributors to racial disparities in blood pressure control. *CircCardiovascQualOutcomes*. 2010; 3(2):173–80. CIRCOUTCOMES.109.860841 [pii];doi: [10.1161/CIRCOUTCOMES.109.860841](https://doi.org/10.1161/CIRCOUTCOMES.109.860841)
22. Beune EJ, Moll van Charante EP, Beem L, Mohrs J, Agyemang CO, Ogedegbe G, et al. Culturally adapted hypertension education (CAHE) to improve blood pressure control and treatment adherence in patients of African origin with uncontrolled hypertension: cluster-randomized trial. *PLoS One*. 2014; 9(3):e90103. doi: [10.1371/journal.pone.0090103](https://doi.org/10.1371/journal.pone.0090103) PMID: [24598584](https://pubmed.ncbi.nlm.nih.gov/24598584/); PubMed Central PMCID: [PMC3943841](https://pubmed.ncbi.nlm.nih.gov/PMC3943841/).
23. Whitlock EP, Orleans CT, Pender N, Allan J. Evaluating primary care behavioral counseling interventions: an evidence-based approach. *AmJPrevMed*. 2002; 22(4):267–84. S0749379702004154 [pii].
24. Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. *AnnInternMed*. 1978; 88(2):251–8.
25. Haafkens JA, Beune EJ, Moll van Charante EP, Agyemang CO. A cluster-randomized controlled trial evaluating the effect of culturally-appropriate hypertension education among Afro-Surinamese and Ghanaian patients in Dutch general practice: study protocol. *BMCHealth ServRes*. 2009; 9:193. 1472-6963-9-193 [pii];doi: [10.1186/1472-6963-9-193](https://doi.org/10.1186/1472-6963-9-193)
26. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *JPsychosomRes*. 1999; 47(6):555–67. S0022399999000574 [pii].
27. Warren-Findlow J, Seymour RB, Brunner Huber LR. The association between self-efficacy and hypertension self-care activities among African American adults. *JCommunity Health*. 2012; 37(1):15–24. doi: [10.1007/s10900-011-9410-6](https://doi.org/10.1007/s10900-011-9410-6)
28. Schoenthaler A, Ogedegbe G, Allegrante JP. Self-efficacy mediates the relationship between depressive symptoms and medication adherence among hypertensive African Americans. *Health EducBehav*. 2009; 36(1):127–37. 1090198107309459 [pii];doi: [10.1177/1090198107309459](https://doi.org/10.1177/1090198107309459)
29. Schofield P, Saka O, Ashworth M. Ethnic differences in blood pressure monitoring and control in south east London. *BrJGenPract*. 2011; 61(585):190–6. doi: [10.3399/bjgp11X567126](https://doi.org/10.3399/bjgp11X567126)
30. Gallant MP, Spitze G, Grove JG. Chronic illness self-care and the family lives of older adults: a synthetic review across four ethnic groups. *JCrossCultGerontol*. 2010; 25(1):21–43. doi: [10.1007/s10823-010-9112-z](https://doi.org/10.1007/s10823-010-9112-z)
31. Kronish IM, Leventhal H, Horowitz CR. Understanding minority patients' beliefs about hypertension to reduce gaps in communication between patients and clinicians. *JClinHypertens(Greenwich)*. 2012; 14(1):38–44. doi: [10.1111/j.1751-7176.2011.00558.x](https://doi.org/10.1111/j.1751-7176.2011.00558.x)
32. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Archives of internal medicine*. 2000; 160(14):2101–7. PMID: [10904452](https://pubmed.ncbi.nlm.nih.gov/10904452/).
33. Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML, et al. Clinical practice guideline for cardiovascular risk management in the Netherlands. *The Netherlands journal of medicine*. 2008; 66(4):169–74. PMID: [18424866](https://pubmed.ncbi.nlm.nih.gov/18424866/).

34. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. *Journal of clinical hypertension*. 2008; 10(5):348–54. PMID: [18453793](#); PubMed Central PMCID: PMC2562622.
35. Ogedegbe G, Schoenthaler A, Richardson T, Lewis L, Belue R, Espinosa E, et al. An RCT of the effect of motivational interviewing on medication adherence in hypertensive African Americans: rationale and design. *ContempClinTrials*. 2007; 28(2):169–81. S1551-7144(06)00046-2 [pii];doi: [10.1016/j.cct.2006.04.002](#)
36. Schoenthaler A, Allegrante JP, Chaplin W, Ogedegbe G. The effect of patient-provider communication on medication adherence in hypertensive black patients: does race concordance matter? *Annals of behavioral medicine: a publication of the Society of Behavioral Medicine*. 2012; 43(3):372–82. doi: [10.1007/s12160-011-9342-5](#) PMID: [22270266](#); PubMed Central PMCID: PMC3665951.
37. Shea S, Misra D, Ehrlich MH, Field L, Francis CK. Correlates of nonadherence to hypertension treatment in an inner-city minority population. *American journal of public health*. 1992; 82(12):1607–12. PMID: [1456334](#); PubMed Central PMCID: PMC1694541.
38. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *MedCare*. 1986; 24(1):67–74.
39. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *JPsycho-somRes*. 2006; 60(6):631–7. S0022-3999(05)00491-5 [pii];doi: [10.1016/j.jpsychores.2005.10.020](#)
40. Fernandez S, Chaplin W, Schoenthaler AM, Ogedegbe G. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. *JBehavMed*. 2008; 31(6):453–62. doi: [10.1007/s10865-008-9170-7](#)
41. Theunissen NC, de Ridder DT, Bensing JM, Rutten GE. Manipulation of patient-provider interaction: discussing illness representations or action plans concerning adherence. *Patient education and counseling*. 2003; 51(3):247–58. PMID: [14630381](#).
42. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. *Journal of human hypertension*. 2004; 18(9):607–13. doi: [10.1038/sj.jhh.1001721](#) PMID: [15029218](#).
43. Parkerson GR Jr., Broadhead WE, Tse CK. Validation of the Duke Social Support and Stress Scale. *FamMed*. 1991; 23(5):357–60.
44. Consumer Quality Index-diabetes. Nivel. 2009-09-06; Utrecht.
45. Harmsen JA, Bernsen RM, Bruijnzeels MA, Meeuwesen L. Patients' evaluation of quality of care in general practice: what are the cultural and linguistic barriers? *Patient education and counseling*. 2008; 72(1):155–62. doi: [10.1016/j.pec.2008.03.018](#) PMID: [18485657](#).
46. Stubbe JH, Brouwer W, Delnoij DM. Patients' experiences with quality of hospital care: the Consumer Quality Index Cataract Questionnaire. *BMC ophthalmology*. 2007; 7:14. doi: [10.1186/1471-2415-7-14](#) PMID: [17877840](#); PubMed Central PMCID: PMC2093924.
47. Stubbe JH, Gelsema T, Delnoij DM. The Consumer Quality Index Hip Knee Questionnaire measuring patients' experiences with quality of care after a total hip or knee arthroplasty. *BMC health services research*. 2007; 7:60. doi: [10.1186/1472-6963-7-60](#) PMID: [17462084](#); PubMed Central PMCID: PMC1876799.
48. Criswell TJ, Weber CA, Xu Y, Carter BL. Effect of self-efficacy and social support on adherence to anti-hypertensive drugs. *Pharmacotherapy*. 2010; 30(5):432–41. doi: [10.1592/phco.30.5.432](#) PMID: [20411995](#); PubMed Central PMCID: PMC4073236.
49. van Es SM, Kaptein AA, Bezemer PD, Nagelkerke AF, Colland VT, Bouter LM. Predicting adherence to prophylactic medication in adolescents with asthma: an application of the ASE-model. *Patient education and counseling*. 2002; 47(2):165–71. PMID: [12191540](#).
50. Brus H, van de Laar M, Taal E, Rasker J, Wiegman O. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. *Patient education and counseling*. 1999; 36(1):57–64. PMID: [10036560](#).
51. Kressin NR, Wang F, Long J, Bokhour BG, Orner MB, Rothendler J, et al. Hypertensive patients' race, health beliefs, process of care, and medication adherence. *Journal of general internal medicine*. 2007; 22(6):768–74. doi: [10.1007/s11606-007-0165-9](#) PMID: [17364243](#); PubMed Central PMCID: PMC2219848.
52. Ogedegbe G, Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. *JClinEpidemiol*. 2003; 56(6):520–9. S0895435603000532 [pii].
53. Maguire LK, Hughes CM, McElnay JC. Exploring the impact of depressive symptoms and medication beliefs on medication adherence in hypertension—a primary care study. *Patient education and counseling*. 2008; 73(2):371–6. doi: [10.1016/j.pec.2008.06.016](#) PMID: [18692978](#).

54. Kohinor MJ, Stronks K, Haafkens JA. Factors affecting the disclosure of diabetes by ethnic minority patients: a qualitative study among Surinamese in the Netherlands. *BMC public health*. 2011; 11:399. doi: [10.1186/1471-2458-11-399](https://doi.org/10.1186/1471-2458-11-399) PMID: [21619571](https://pubmed.ncbi.nlm.nih.gov/21619571/); PubMed Central PMCID: PMC3130672.
55. Home R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. *PLoS One*. 2013; 8(12):e80633. doi: [10.1371/journal.pone.0080633](https://doi.org/10.1371/journal.pone.0080633) PMID: [24312488](https://pubmed.ncbi.nlm.nih.gov/24312488/); PubMed Central PMCID: PMC3846635.
56. Agyemanga CSK, Snijdera MB, Beunea EJ, van den Born BJ, Brewster LM, Ujcic-Voortman JJ, et al. Hypertension control in a large multi-ethnic cohort in Amsterdam, the Netherlands: The HELIUS study. *International Journal of Cardiology*. 2015;doi: [10.1016/j.ijcard.2015.01.061](https://doi.org/10.1016/j.ijcard.2015.01.061) (Available online 27 January 2015).
57. Serour M, Alqhenaei H, Al-Saqabi S, Mustafa AR, Ben-Nakhi A. Cultural factors and patients' adherence to lifestyle measures. *The British journal of general practice: the journal of the Royal College of General Practitioners*. 2007; 57(537):291–5. PMID: [17394732](https://pubmed.ncbi.nlm.nih.gov/17394732/); PubMed Central PMCID: PMC2043336.
58. Practitioners RCoG. Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. NICE Clinical Guidelines, No 76. 2009;(National Collaborating Centre for Primary Care (UK)):Par. 7.3.
59. Ye S, Krupka DJ, Davidson KW. Diagnosing medication non-adherence in a patient with myocardial infarction. *Frontiers in psychology*. 2012; 3:267. doi: [10.3389/fpsyg.2012.00267](https://doi.org/10.3389/fpsyg.2012.00267) PMID: [22876236](https://pubmed.ncbi.nlm.nih.gov/22876236/); PubMed Central PMCID: PMC3411184.
60. Agyemang C, Bindraban N, Mairuhu G, Montfrans G, Koopmans R, Stronks K. Prevalence, awareness, treatment, and control of hypertension among Black Surinamese, South Asian Surinamese and White Dutch in Amsterdam, The Netherlands: the SUNSET study. *JHypertens*. 2005; 23(11):1971–7. 00004872-200511000-00009 [pii].
61. Bray P, Thompson D, Wynn JD, Cummings DM, Whetstone L. Confronting disparities in diabetes care: the clinical effectiveness of redesigning care management for minority patients in rural primary care practices. *J Rural Health*. 2005; 21(4):317–21. PMID: [16294654](https://pubmed.ncbi.nlm.nih.gov/16294654/).
62. Rahaghi FF, Chastain VL, Benavides R, Ferrer G, Ramirez J, Mehta J, et al. Shared medical appointments in pulmonary hypertension. *Pulm Circ*. 2014; 4(1):53–60. doi: [10.1086/674883](https://doi.org/10.1086/674883) PMID: [25006421](https://pubmed.ncbi.nlm.nih.gov/25006421/); PubMed Central PMCID: PMC4070761.